Penetrance of <i>CHEK2</i> and <i>BRCA1</i> Double Heterozygotes in Breast and/or Ovarian Cancer Patients-Reference-Cited by-同舟云学术

Penetrance of CHEK2 and BRCA1 Double Heterozygotes in Breast and/or Ovarian Cancer Patients

Published:2023-04-01 Issue:2 Volume:77 Page:137-140
ISSN:2255-890X
Container-title:Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
language:en
Short-container-title:

Author:

Berga-Švītiņa Egija¹,Pirsko Valdis¹,Nakazawa-Miklaševiča Miki¹²,Maksimenko Jeļena¹²³,Gardovskis Jānis¹²³,Miklaševičs Edvīns¹²

Affiliation:

1. 1 Institute of Oncology , Rīga Stradiņš University , 13 Pilsoņu Str., Rīga, LV-1002 , Latvia

2. 2 Faculty of Medicine , Rīga Stradiņš University , 16 Dzirciema Str., Rīga, LV-1007 , Latvia

3. 3 Pauls Stradiņš Clinical University Hospital , 13 Pilsoņu Str., Rīga, LV-1002 , Latvia

Abstract

Abstract Germline pathogenic BRCA1 variants confer increased risk of breast and/or ovarian cancer. The penetrance of BRCA1 pathogenic variants is variable due to the effects of other genetic factors. The interaction between CHEK2 and BRCA1 proteins is crucial in homology directed DNA repair pathway. The aim of this study was to assess the effect of three pathogenic/likely pathogenic variants of the CHEK2 gene on BRCA1 pathogenic allelic variant penetrance. The analysis included 380 DNA samples of women with confirmed positive BRCA1 status for one of founder variants c.4035del and c.5266dup. The c.444+1G>A and c.470T>C variants of CHEK2 gene were identified by Sanger’s sequencing, and the del5395 variant was detected by multiplex PCR. The studied CHEK2 variants were found in 13 double heterozygous cases (c.444+1G>A, n = 1; c.470T>C, n = 11, del5395, n = 1). Although the prevalence of CHEK2 variants in the ovarian cancer group was comparatively high (5.41%), the increase of the ovarian cancer risk was not statistically significant (OR = 1.56; 95% CI: 0.32–9.94; p = 0.73). The association of the age at the onset of cancer with the presence of particular CHEK2 variant was not consistent.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/prolas-2023-0020

Reference22 articles.

1. Chen, S, Parmigiani, G. (2007). Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol., 25 (11), 1329–1333.

2. Cybulski, C., Gorski, B., Huzarski, T., Masojc, B., Mierzejewski, M., Debniak, T., Teodorczyk, U., Byrski, T., Gronwald, J., Matyjasik, J., et al. (2004). CHEK2 is a multiorgan cancer susceptibility gene. Amer. J. Hum. Genet., 75 (6), 1131–1135.

3. Cybulski, C., Wokolorczyk, D., Huzarski, T., Byrski, T., Gronwald, J., Gorski, B., Debniak, T., Masojc, B., Jakubowska, A., Gliniewicz, B., et al. (2006). A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J. Med. Genet., 43 (11), 863–866.

4. Cybulski, C., Wokolorczyk, D., Kladny, J., Kurzawski, G., Suchy, J., Grabowska, E., Gronwald, J., Huzarski, T., Byrski, T., Gorski, B., et al. (2007). Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Eur. J. Hum. Genet., 15 (2), 237–241.

5. Cybulski, C., Gorski, B., Huzarski, T., Byrski, T., Gronwald, J., Debniak, T., Wokolorczyk, D., Jakubowska, A., Serrano-Fernandez, P., Dork, T et al. (2009). Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations. J. Med. Genet., 46 (2) 132–135.